9:00am - 5:00pm

Our Opening Hours Mon. - Fri.

1.800.799.2234

Call Us For Free Consultation

Facebook

Twitter

Search
 

Continuous 24h Intravenous Infusion of Mithramycin, an Inhibitor of Cancer Stem Cell Signaling, in People With Primary Thoracic Malignancies or Carcinomas, Sarcomas or Germ Cell Neoplasms With Pleuropulmonary Metastases

Top West Virginia Mesothelioma Lawyer | Law Firm | Attorney | GPW > Continuous 24h Intravenous Infusion of Mithramycin, an Inhibitor of Cancer Stem Cell Signaling, in People With Primary Thoracic Malignancies or Carcinomas, Sarcomas or Germ Cell Neoplasms With Pleuropulmonary Metastases

Continuous 24h Intravenous Infusion of Mithramycin, an Inhibitor of Cancer Stem Cell Signaling, in People With Primary Thoracic Malignancies or Carcinomas, Sarcomas or Germ Cell Neoplasms With Pleuropulmonary Metastases

Estimated reading time: < 1 min

Condition: Esophageal Neoplasms

Estimated Enrollment: 100

Gender: All

Min Age: 18 Years

Age Group: Adult, Older Adult

Current Status: Recruiting

Study Results: No Results Available

Outcome Measures: Maximum tolerated dose,  Overall response rate,  ,

Interventions: Mithramycin,

Phase:

Study Type: Interventional

Study Design: Allocation: Non-Randomized, Intervention Model: Sequential Assignment, Masking: None (Open Label),Primary Purpose: Treatment

Primary Completion Date: August 3, 2028

Completion Date: August 3, 2028

Last  Posted Date: July 4, 2019

Location: National Institutes of Health Clinical Center, Bethesda, Maryland, United States

Website Link: https://ClinicalTrials.gov/show/NCT02859415

Was this article helpful?
Dislike 0